Regulating clinical trials in Europe

The Lancet Oncology

Volumn 14, Issue 6, 2013, Pages 453-454

  Willmott, Glenis ^a  

^a European Parliament   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RESEARCH; CLINICAL RESEARCH; DRUG INDUSTRY; EUROPE; EUROPEAN UNION; INSURANCE; LAW; LEGAL ASPECT; LETTER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; EUROPE; EUROPEAN UNION; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION;

EID: 84876990869     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70071-8     Document Type: Letter

References (5)

1. Fostering EU's attractiveness in clinical research: Commission proposes to revamp rules on trials with medicines 2012, European Commission, European Commission, Brussels.
2. Proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC 2012, European Commission, European Commission, Brussels.
3. Impact assessment report on the revision of the " Clinical Trials Directive" 2001/20/EC 2012, European Commission, European Commission, Brussels.
4. The AllTrials campaign AllTrials, (accessed March 16, 2013). http://www.alltrials.net/blog/the-alltrials-campaign/.
5. Draft report on the proposal for a regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC 2012, European Parliament Committee on the Environment, Public Health and Food SafetyPublic Health and Food Safety, European Parliament, Brussels.